A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2017 - Product Thumbnail Image

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2017

  • Report
  • 45 Pages
From
Bispecific Antibodies: Clinical Trial Tracker - Product Thumbnail Image

Bispecific Antibodies: Clinical Trial Tracker

  • Clinical Trials
From
Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors - Product Thumbnail Image

Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

  • Report
  • 1342 Pages
From
Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence - Product Thumbnail Image

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

  • Report
  • 171 Pages
From
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence - Product Thumbnail Image

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence

  • Report
  • 170 Pages
From
Peptide Therapeutics in Metabolic Disorders, 2016 - 2025 - Product Thumbnail Image

Peptide Therapeutics in Metabolic Disorders, 2016 - 2025

  • Report
  • 436 Pages
From
Myelodysplastic Syndrome - Pipeline Review, H2 2017 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H2 2017

  • Report
  • 962 Pages
From
Myelodysplastic Syndrome - Pipeline Review, H1 2017 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H1 2017

  • Report
  • 865 Pages
From
Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies - Product Thumbnail Image

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

  • Report
  • 131 Pages
From
Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 587 Pages
From
Chronic Heart Failure Global Clinical Trials Review, H1, 2017 - Product Thumbnail Image

Chronic Heart Failure Global Clinical Trials Review, H1, 2017

  • Clinical Trials
  • 273 Pages
From
2018 Oral Mucositis Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Oral Mucositis Drug Development- Pipeline Analysis Report

  • Report
  • 70 Pages
From
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018 - Product Thumbnail Image

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018

  • Report
  • 1000 Pages
From
Cardiovascular Disorders Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Cardiovascular Disorders Drug Development Pipeline Review, 2017

  • Report
  • 432 Pages
From
2018 Atrial Fibrillation Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Atrial Fibrillation Drug Development- Pipeline Analysis Report

  • Report
  • 70 Pages
From
T-cell Immunotherapy: Clinical Trial Tracker - Product Thumbnail Image

T-cell Immunotherapy: Clinical Trial Tracker

  • Clinical Trials
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • Report
  • 187 Pages
From
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • Report
  • 169 Pages
From
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016

  • Report
  • 173 Pages
From
Loading Indicator
adroll